Treatment of Diabetic Nephropathy with Chronic Kidney Disease and Established Atherosclerotic Cardiovascular Disease

This protocol addresses patients with type 1 or type 2 diabetes mellitus who have diabetic nephropathy in the setting of chronic kidney disease and established atherosclerotic cardiovascular disease. The presence of all three conditions defines a high-risk population requiring a specific, evidence-based approach.

Secondary cardiovascular prevention is a central priority in this combination. Antiplatelet therapy is indicated — the complete protocol defines the specific agent and the precise clinical parameters that govern its use in this setting.